PINX1 and bladder transitional cell carcinoma: The prostate adenocarcinoma (TCGA, Provisional), colorectal adenocarcinoma (TCGA, Provisional), head and neck squamous cell carcinoma (TCGA, Provisional), kidney renal clear cell carcinoma (TCGA, Provisional), lung adenocarcinoma (TCGA, Provisional), lung squamous cell carcinoma (TCGA, Provisional), bladder urothelial carcinoma (TCGA, Provisional) and ovarian serous cystadenocarcinoma (TCGA, Provisional) were randomly selected to observe the relationship between PinX1 gene alteration and patient’s survival.